Defencath was CorMedix’s largest product and service line in fiscal 2025, bringing in $258.81M of $311.71M (83%).
| Product and Service | FY 2024 | FY 2025 |
|---|---|---|
| Defencath | $43.47M | $258.81M |
| Melinta Portfolio | — | $45.53M |
| Product Sales, Net | $43.47M | — |
| Contract Revenue | — | $7.37M |
| Total | $86.94M | $311.71M |
CorMedix brought in $311.71M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. CorMedix regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $86.94M. Defencath was the largest at $258.81M (83.0%), ahead of Melinta Portfolio at $45.53M (14.6%) and Contract Revenue at $7.37M (2.4%).
CorMedix began breaking out Melinta Portfolio in fiscal 2025 and Contract Revenue in fiscal 2025. CorMedix stopped reporting Product Sales, Net as a separate line after fiscal 2024, when it brought in $43.47M.
CorMedix (CRMD) reports its revenue by product and service. In fiscal 2025, Defencath was its largest product and service line, bringing in $258.81M (83.0% of the total), followed by Melinta Portfolio at $45.53M (14.6%).
Defencath was CorMedix's largest product and service line in fiscal 2025, bringing in $258.81M, or 83.0% of the $311.71M total across its three product and service lines.
Every figure comes from CorMedix's annual financial filings, as reported. Each line keeps the name CorMedix gives it, and years follow its fiscal calendar.
CorMedix's revenue by product and service goes back to fiscal 2024, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.